The study, released today and with a sample of 432 people, focuses not only on the amount of antibodies generated but also on their performance.
After several months of follow-up of the patients, the results obtained showed that, initially, both the number and the performance of the antibodies were higher among the patients inoculated with two doses of the vaccine Pfizer that between people who had gone through the disease.
Over time, however, while the amount of antibodies continued to fall in both groups-faster in the first than in the second-their performance worsened among those vaccinated while improving among those recovered.
On the other hand, and to the surprise of the researchers, the analyzed data showed also that the amount and performance of the antibodies of the patients recovered with a body mass index of 30 or higher (in the range of obesity) were higher during the different periods studied, that of those with a BMI less than 30 (overweight or normal weight).
This, they noted, suggests that people with obesity who passed the disease are…
“Travel enthusiast. Alcohol lover. Friendly entrepreneur. Coffeeaholic. Award-winning writer.”